Tacrolimus Versus Mometasone for Dyshidrotic Hands: Improvement Did Not Prevent Relapse
When recurring palm blisters disrupt typing, climbing or handling equipment, an early improvement can feel like the entire treatment story. A small trial comparing tacrolimus and mometasone shows why the weeks after a treatment course deserve equal attention.
The study compared two hands within the same person
The primary January 2002 trial abstract reports 16 patients in a randomized, observer-blinded, intrapersonal comparison. Investigators compared tacrolimus 0.1% ointment with mometasone furoate 0.1% ointment for dyshidrotic palmar eczema. An intrapersonal design compares treated areas within a person, helping control some differences between patients. It does not turn 16 people into a large independent two-group trial.
After a two-week washout, active treatment lasted four weeks with twice-daily applications and emollients permitted as needed. Weekly monitoring continued up to eight weeks. These were research instructions, not a universal dosing plan to copy from a blog. The accessible primary abstract is the basis for the numerical results discussed here; it does not provide every protocol or safety detail available in the full paper.
| Finding | What it tells the reader | What it does not establish |
|---|---|---|
| More than 50% reduction in baseline DASI after two weeks on both treated palmar areas | Both areas improved during treatment | A 50% cure rate or equal efficacy |
| Tacrolimus p=0.003; mometasone p=0.022 | Each within-treatment change was statistically significant | That tacrolimus was superior because its p value was smaller |
| 14 of 16 patients needed further therapy for recurrence within three weeks after active treatment | Relapse was common in this small study | The long-term relapse probability for every patient |
Why comparing the two p values would be a mistake
DASI measures dyshidrotic area and severity. The abstract’s p values describe changes from baseline for each treatment. They are not a reported direct superiority test between treatments. Likewise, observing improvement in both hands cannot prove noninferiority or equivalence. Those conclusions require appropriate comparisons and a study designed to answer them.
The 14 recurrences equal 87.5% of the small study sample. That arithmetic is useful only with its denominator and short follow-up attached. It indicates that reducing active signs and maintaining control are different goals. The authors discussed a possible rotational role for tacrolimus; the study did not define the best long-term rotation schedule for an individual patient.
Dyshidrotic eczema and the U.S. indication are different questions
The American Academy of Dermatology’s treatment guidance explains that clinicians may prescribe tacrolimus for recurring dyshidrotic eczema. It also distinguishes that use from the FDA-approved atopic dermatitis indication. Ask the prescriber which diagnosis is being treated and whether the use is off label.
The current tacrolimus label describes second-line, short-term and noncontinuous chronic treatment for specified patients with moderate-to-severe atopic dermatitis. Only 0.03% is indicated for children aged 2–15; the 0.1% ointment studied here must not be substituted into a young child’s routine. The boxed warning states that long-term safety is not established, notes rare malignancy reports without an established causal relationship, and advises against continuous long-term use.
Common local effects can include burning or stinging. The label also advises avoiding ultraviolet therapy, sun lamps and tanning beds during treatment. Do not independently combine prescriptions or copy a study schedule. Our tacrolimus and pimecrolimus guide and cancer-risk evidence explanation provide related context without canceling the product instructions.
Plan for the end of treatment before the end arrives
At a visit, ask what improvement to expect, when to reassess, and exactly what to do if blisters recur. Bring a record of wet work, gloves, products, sweating and practical limitations. Our hand-blister guide explains why moisturizer alone may be insufficient. The sweating discussion separates a possible contributor from the skin diagnosis.
Dr. Arsy Moisturizer #003, 4 oz offers cosmetic hydration, moisture-barrier support and ordinary dry-skin comfort. It was not an evaluated study treatment, does not prevent these relapses and is not a substitute for anti-inflammatory medicine. Ask which moisturizer and application sequence fit the prescription plan.
Adult educational information, checked November 9, 2026. The realistic AI-created gym image is illustrative, not a treatment testimonial.